Opus Point Partners Management’s Karyopharm Therapeutics KPTI Stock Holding History

Opus Point Partners Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-3,333	Closed	-$671K	–	52
2018 Q1	$671K	Sell	3,333 -3,334	-50%	-$665K	1.32%	26
2017 Q4	$960K	Hold	6,667	–	–	0.83%	36
2017 Q3	$1.1M	Hold	6,667	–	–	0.99%	33
2017 Q2	$905K	Buy	+6,667	New	+$987K	0.83%	38
2016 Q2	–	Sell	-3,300	Closed	-$442K	–	49
2016 Q1	$442K	Sell	3,300 -700	-18%	-$77.3K	0.34%	47
2015 Q4	$795K	Buy	4,000 +3,017	+307%	+$653K	0.53%	48
2015 Q3	$155K	Buy	+983	New	+$263K	0.09%	53
2015 Q2	–	Sell	-1,000	Closed	-$459K	–	61
2015 Q1	$459K	Buy	+1,000	New	+$431K	0.38%	55

Other funds holding KPTI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Opus Point Partners Management's KPTI Position: Q2 2018 in Review

Opus Point Partners Management sold out of Karyopharm Therapeutics (KPTI) in Q2 2018, closing a stake of 3,333 shares — an estimated $671K sold.

Opus Point Partners Management first reported a position in KPTI in Q1 2015 and held it in 8 quarters. The position peaked at $1.1M in Q3 2017. 108 funds tracked by Wall St. Rank hold KPTI as of Q2 2018.

Opus Point Partners Management reported no remaining Karyopharm Therapeutics position as of Q2 2018 after selling out during the quarter.
Opus Point Partners Management sold 3,333 Karyopharm Therapeutics shares in Q2 2018, an estimated $671K.
Opus Point Partners Management first reported a position in Karyopharm Therapeutics in Q1 2015 and held it in 8 quarters.
Opus Point Partners Management's Karyopharm Therapeutics position peaked at $1.1M in Q3 2017.
108 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2018.

Based on Opus Point Partners Management's 13F filing for Q2 2018, filed 14 Aug 2018.